Durable Responses Seen with Cilta-Cel at 18 Months in Relapsed/Refractory Multiple Myeloma
June 8th 2021Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More
In R/R B-NHL, High Marks Achieved by C-CAR066
June 8th 2021A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Read More
Pimitespib Shows Significant PFS Improvement in Advanced Refractory GIST
June 8th 2021Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.
Read More
Teclistamab at Recommended Phase 2 Dose Shows Promising Results in R/R Myeloma
June 8th 2021According to updated results presented during the 2021 ASCO Annual Meeting, teclistamab administered at the recommended phase 2 dose demonstrated encouraging safety and efficacy among patients with relapsed/refractory multiple myeloma treated in a first-in-human phase 1 trial.
Read More
In Transplant-Eligible, Newly Diagnosed MM, KCd Consolidation Proves Noninferior to ASCT
June 8th 2021In newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation.
Read More
Fracture Risk Reduced by BPAs During Radium-223/Enzalutamide Combo Treatment In mCRPC
June 8th 2021The risk of fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer was controlled by the use of bone-protecting agents during treatment with radium-223 plus enzalutamide.
Read More
Panitumumab Maintenance Combination Prolongs PFS in RAS Wild-Type mCRC
June 8th 2021In the phase 2 PANAMA trial, adding panitumumab to 5-fluorouracil and leucovorin showed significant improvement in progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Read More
Trastuzumab Deruxtecan Sustains Efficacy Benefit in HER2-Positive mCRC
June 8th 2021With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.
Read More
Tisagenlecleucel Elicits Impressive and Durable Responses in Relapsed/Refractory Follicular Lymphoma
June 7th 2021In the phase 2 ELARA trial, treatment with the autologous CD19-directed chimeric antigen receptor T-cell therapy, tisagenlecleucel, achieved a high response rate that appeared durable, in patients with relapsed/refractory follicular lymphoma.
Read More
First-Line Treatment Ibrutinib Plus Venetoclax Inhibits Response in CLL/SLL
June 7th 2021Over half, 56%, of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who were treated with The combination of ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery
Read More
Pertuzumab Plus Trastuzumab Demonstrates Clinical Activity in ERBB2/ERBB3+ Uterine Cancer
June 7th 2021In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.
Read More
Frontline Ibrutinib/Venetoclax Combination Induces Responses in CLL/SLL
June 7th 2021Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with the combination of ibrutinib plus venetoclax had complete response and complete response with a 56% incomplete bone marrow recover rate in the phase 2 CAPTIVATe study.
Read More
Pembrolizumab/Lenvatinib Combo Supported by HRQOL Analysis From CLEAR Trial in Frontline RCC
June 7th 2021Similar health-reatled quality of life outcomes and disease-related symptom scores were seen between the combination of lenvatinib plus pembrolizumab and sunitinib for the frontline treatment of metastatic renal cell carcinoma.
Read More
Across 3 HER2-negative biomarker signature groups, treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel increased estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer, but the results were not considered significant, according to findings from the phase 2 I-SPY 2 trial.
Read More